What dose ranges appear in the research?

Published intranasal protocols most commonly investigate roughly 200–600 mcg per administration across two or three daily portions, over ten to fourteen days. Parenteral animal work reports amounts around 50 mcg per kg bodyweight. All figures describe research protocols, not guidance for human use.

How much bacteriostatic water suits the 10 mg vial?

Laboratory practice typically dissolves a 10 mg vial in 2 ml of bacteriostatic water, giving a 5 mg/ml solution in which 300 mcg occupies 0.06 ml. A 1 ml fill gives the more concentrated 10 mg/ml solution used in intranasal preparations. The reconstitution calculator on this page converts any volume.

How stable is the reconstituted solution?

Once mixed with bacteriostatic water, the solution remains stable for up to 28 days when refrigerated at 2–8 °C and protected from light. Sealed lyophilised vials are best stored at -20 °C.

Is this product for human use?

No. All AKH BioLabs products are supplied strictly for laboratory research. They are not approved for human consumption, and nothing on this page is medical advice.

Who tests this product?

A named laboratory outside AKH, on a report ordered by our manufacturer. The laboratory verification section on this page publishes that Certificate unaltered, or shows "Certificate pending" until a matching report has been published.

Popular

Cognitive· Popular

In stock

Semax

Name: Semax
Brand: AKH BioLabs
SKU: semax
Price: 56 USD
Availability: InStock

Semax Heptapeptide

Semax is supplied as 10mg lyophilised powder for laboratory research. Price is shown in your currency, and its Certificate from a named outside laboratory is published on this page. Not for human or veterinary use.

Size10mgPurity99.93%FormulaC39H54N10O10S

Semax is a synthetic seven-amino-acid analogue of the ACTH(4-10) fragment, developed by Russia's Institute of Molecular Genetics and approved in Russia for cerebrovascular indications. It is researched as a nootropic and neuroprotective probe, with reported effects on BDNF expression, dopaminergic and serotonergic tone, and ischaemic-injury models.

€50

Quantity

HPLC verified

9–14 day shipping

Full COA

Worldwide delivery

About this compound

The research profile.

Semax is a synthetic heptapeptide consisting of the ACTH(4-7) fragment Met-Glu-His-Phe joined to a Pro-Gly-Pro tail. The parent fragment carries none of the corticotropic activity of full-length ACTH, and the Pro-Gly-Pro extension slows peptidase degradation enough for intranasal and parenteral study designs to be workable.

The best-developed line of research concerns neurotrophic signalling. Rodent studies report that Semax raises brain-derived neurotrophic factor protein in the basal forebrain, and separate work describes coordinated changes in BDNF and trkB expression in the hippocampus, with time-course comparisons against nerve growth factor across hippocampus, frontal cortex, and retina. Transcriptome-level analyses in cerebral ischaemia-reperfusion models describe broad shifts in inflammatory and neurotrophic gene programmes rather than a single defined target.

Semax is registered as a medicine in Russia, and much of the clinical record — principally in ischaemic stroke and related indications — is published in Russian-language journals. That literature has not been reproduced in large international trials, so the strength of evidence should be weighed accordingly.

Published research

18 peer-reviewed studies on Semax are summarised in our research library, including 10 published since 2023 — with study designs, reported findings and what the evidence does not establish.

Read the Semax evidence base

For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.

Categorised as Cognitive — Neuropeptides for neuroscience research.

Dosing at a glance

What the literature reports.

For research and laboratory use only. Not for human consumption.

Route

Intranasal

Frequency

2–3x daily

Reported range

200–600 mcg

Protocol duration

10–14 days

200 mcgper administration600 mcg

Subcutaneous · Once daily · 200–500 mcg per administration · 1–3 weeks

Intranasal instillation of a dilute aqueous solution is the route used across the Russian clinical literature, with divided daily portions over a ten-to-fourteen day course. Higher amounts appear in the acute-stroke protocols specifically.

Ranges reflect protocols reported in the published literature on Semax — see research citations.

Calculate a dilution

Reconstitution & storage

From powder to solution.

Step 01
Add 2 ml bacteriostatic water
Aim the stream at the vial wall rather than the powder.
Step 02
Swirl gently — never shake
Rotate the vial until the solution runs clear. Agitation degrades the peptide.
Step 03
Refrigerate at 2–8 °C
Reconstituted vials belong in the fridge, protected from direct light.
Step 04
Use within 28 days
Discard any remainder once the stability window closes.

Lyophilised · −20 °CReconstituted · 2–8 °C, 28 days

A 10 mg vial in 2 ml of bacteriostatic water gives a 5 mg/ml solution; a 1 ml fill gives 10 mg/ml, which is closer to the concentrated solutions described in intranasal protocols.

Reconstitution calculator

10 mg vial

Vial amount

Bacteriostatic water

Amount per draw

mcg

300 mcg = 0.3 mg

Draw

6units · U-100 insulin syringe

Concentration: 5 mg/ml
Draws per vial: 33
Cost per draw: €1.52

For research and laboratory use only. Not for human consumption.

Laboratory arithmetic for Semax — enter the COA-verified vial content for exact figures. Not medical advice.

Open the full calculator for this vial

Effect timeline

Observed across the research window.

Milestones summarise findings reported in the cited studies. Outcomes vary across models and protocols.

Start

Early distribution and binding

Binding studies report specific interaction in rat basal forebrain tissue, with BDNF protein differences measurable in the hours following administration.

Days 1–5

Neurotrophic expression dynamics

Time-course work describes coordinated BDNF and trkB expression changes in hippocampus, with comparative NGF dynamics tracked across frontal cortex and retina over the first days of administration.

Week 2

Clinical course end points

The Russian stroke literature reports functional and neurological scale comparisons at the conclusion of a ten-to-fourteen day intranasal course.

Week 4

Transcriptome-level comparisons

Ischaemia-reperfusion studies profile gene expression at later time points, describing sustained differences in inflammatory and neurotrophic programmes relative to controls.

Start

Early distribution and binding

Binding studies report specific interaction in rat basal forebrain tissue, with BDNF protein differences measurable in the hours following administration.

Days 1–5

Neurotrophic expression dynamics

Time-course work describes coordinated BDNF and trkB expression changes in hippocampus, with comparative NGF dynamics tracked across frontal cortex and retina over the first days of administration.

Week 2

Clinical course end points

The Russian stroke literature reports functional and neurological scale comparisons at the conclusion of a ten-to-fourteen day intranasal course.

Week 4

Transcriptome-level comparisons

Ischaemia-reperfusion studies profile gene expression at later time points, describing sustained differences in inflammatory and neurotrophic programmes relative to controls.

For research and laboratory use only. Not for human consumption.

Scientific research

The published evidence.

The dosing ranges and timeline milestones on this page summarise the peer-reviewed publications below.

References

01
Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem (2006). PubMed · 16635254
02
Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res (2006). PubMed · 16996037
03
Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci (2010). PubMed · 19662538
04
Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes (Basel) (2020). PubMed · 32580520
05
[The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova (2018). PubMed · 29798983

Laboratory verification

One Certificate, published unaltered.

The Certificate is a test report from a named laboratory outside AKH, ordered by our manufacturer and shown here exactly as the laboratory issued it. A printed copy ships in every parcel.

Batch: 26104
Test date: 31 Jul 2026
Task ID: #1812400
Purity: 99.93%

Verified by Brown Institute of Biomolecular Research. Scan the full report for every measurement.

Product FAQ